Targets › ANXA5
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology.
This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade. (UniProt, P08758)
Open in Phaseline: the race on ANXA5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Annexin Pharmaceuticals | ANXV Human recombinant Annexin A5 protein; proposed mechanism involves binding to phosphatidyls | ANXA5 | Phase 2 | Non-Proliferative Diabetic Retinopathy | – |
Non-Proliferative Diabetic Retinopathy (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.